OncoMatch/Clinical Trials/NCT05629546
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
Is NCT05629546 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Cytokine-induced memory-like natural killer cells and Relatilmab for advanced melanoma.
Treatment: Cytokine-induced memory-like natural killer cells · Relatilmab · Nivolumab — This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with advanced and/or metastatic melanoma. There will be two arms to test the variables of ML NK cell source. ML NK cells from an autologous source will be used for Arm 1, and ML NK cells from an allogeneic source will be used for Arm 2. The investigators hypothesize that ML NK cells from either an autologous source or allogeneic source are safe and tolerable in subjects with advanced and/or metastatic melanoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Metastatic disease required
advanced or metastatic melanoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1/PD-L1 therapy (nivolumab, pembrolizumab, atezolizumab, durvalumab)
progressed after at least 12 weeks or a minimum of 2 doses of treatment with a standard of care PD1/PDL1 containing therapy (nivolumab, pembrolizumab, atezolizumab, or durvalumab)
Cannot have received: tumor infiltrating lymphocytes therapy
received prior tumor infiltrating lymphocytes (TIL) therapy (either in the setting of clinical trial or standard of care if TIL therapy is FDA approved in the future)
Lab requirements
Kidney function
creatinine within normal institutional limits or creatinine clearance > 40 ml/min/1.73 m^2 by cockcroft-gault formula
Liver function
total bilirubin < 2 mg/dl; ast(sgot)/alt(sgpt) < 3.0 x uln
Cardiac function
oxygen saturation ≥ 90% on room air; ejection fraction ≥ 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify